Drug Approval | February 15, 2026
NATCO receives CDSCO approval for Semaglutide in India
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Poviztra is a second brand of Wegovy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
